Scienter Allegations Now Sufficient In Specialty Drug Maker’s Stock-Drop Suit

(March 3, 2021, 1:30 PM EST) -- PHILADELPHIA — In denying a motion to dismiss for failure to state a claim for relief, a federal judge in Pennsylvania on March 1 ruled that the lead plaintiff in a securities class action against a specialty pharmaceutical company and three of its senior executives has sufficiently pleaded scienter in alleging that the defendants acted with the required state of mind in misrepresenting the efficacy and manufacturing quality control for the development of the company’s non-opioid therapeutic drug candidate....

Attached Documents

Related Sections